|
Tuesday, 19 August 2003: 08:00-17:00
River Exhibition Hall (Sheraton Hotel and Towers) |
PB Tuesday Poster Sessions |
|
| | PB-001 Galantamine for Parkinson's Disease with Dementia
Dag Aarsland, Michael Hutchinson |
| | PB-002 Effects of Risperidone on Psychometric and Cognitive Functions in Healthy Elderly Volunteers
Hervé Allain, Christophe Tessier, Philippe Bouhours |
| | PB-003 Caregiver Burden and Quality of Life in Alzheimer’s Disease
Ricardo F. Allegri, Fernando E Taragano, Raul L Arizaga, Diego Sarasola, Leandro Lon, Cecilia Serrano, Judith Butman |
| | PB-004 Brief Alzheimer Screen (BAS)
J. Wesson Ashford, Frederick A. Schmitt, Marta Mendiondo, Richard Kryscio |
| | PB-005 Implementation of an Integrated Approach to the Treatment of Alzheimer's Disease in Primary Care
Mary Guerriero Austrom, Teresa Damush, Hugh Hendrie, Christopher Callahan, Malaz Boustani |
| | PB-006 Effect of Memory and Activites of Daily Living Training in Mild Alzheimer's Disease Patients
Renata Avila, isabel Albuquerque de carvalho, Cássio Machado de Campos Bottino, eliane Miotto |
| | PB-007 Memantine Provides Neuroprotection in Animal Models at Therapeutically Relevant Doses
Wojciech Danysz, Hans-Jörg Möbius, Chris Parsons, Guenter Quack, Gary Wenk, Pradeep Banerjee, Albrecht Stöffler |
| | PB-008 Predictors of Institutionalization in People with Dementia
Sube Banerjee |
| | PB-009 Addition of Donepezil for Treatment of Psychotic Symptoms in Patients with Dementia of the Alzheimer’s Type
Joseph Bergman, Izidor Brettholz, Michael Shneidman, Vladimir Lerner |
| | PB-010 Treatment of Older Adults with Late Life Depression and Comorbid Personality Disorders
John Leslie Beyer, Leslie Horton, Steven Thorp, Jennifer Cheavens, Thomas Lynch |
| | PB-011 Concurrent Use of Donepezil and ECT
Ravi S Bhat, Prashanth Mayur, Indranil Chakrabarti |
| | PB-012 Rate of Cognitive Decline in MCI
Leszek Bidzan |
| | PB-013 Galantamine Demonstrates a Consistent 12-month Treatment Response in Patients with Dementia
Rafael Blesa, Paul Kershaw, Atul R. Mahableshwarkar |
| | PB-014 Preliminary Data on Discriminative Validity and Normative Data for a Spanish Version of the Memory Impairment Screen (MIS)
Peter Böhm, Jordi Peña-Casanova, Rosa Maria Manero, Carmen Terron, Nina Gramunt, Stella Badenas |
| | PB-015 Long-Term Treatment with Donepezil and Rivastigmine Treatment:the Effect on Cognition
Alina Borkowska, Marzena Zió³kowska, Ewa Pilaczyñska, Andrzej Kêpa, Janusz Rybakowski |
| | PB-016 Mini-Cog
Soo Borson, James Scanlan |
| | PB-017 Violent Behavior Associated with Acetylcholinesterase Inhibitors and Liability of Prescribers of Donepezil
Janet K. Brewer |
| | PB-018 Alzheimer's Treatment Using Galantamine: Interim Results from the Nature Study
Henry Brodaty, Michael Woodward, Karyn L Boundy |
| | PB-019 The GPCOG: A Screening Test for Dementia for Use in Primary Care
Henry Brodaty |
| | PB-020 A Long-Term Comparison of Galantamine and Donepezil in the Treatment of Moderate-to-Severe Alzheimer's Disease: A Responder Analysis
Roger Bullock, Atul R. Mahableshwarkar, Sean Lilienfeld |
| | PB-021 Donepezil-Treated VaD Patients Demonstrate Global Benefits: A Comparison of the CIBIC-Plus Versus CDR-SB
Alistair Burns, Raymond D Pratt, Carlos A Perdomo |
| | PB-022 Memory Impairment Screen (MIS)
Herman Buschke |
| | PB-023 Antidepressant Efficacy Of Moclobemide In Old Age: An Open Study
Sibel Cakir, Isin Baral Kulaksizoglu |
| | PB-024 Clinical Presentation of Late Onset Mania in a Turkish Sample
Sibel Cakir, Isin Baral Kulaksýzoglu |
| | PB-025 Co-factors of Dementia – Consequences for Pharmacotherapy of Alzheimer's Disease with Donepezil?
Pasquale Calabrese, Martin Kamleiter, Julia Moebius |
| | PB-026 Measuring Dementia-Specific Quality of Life: Resident, Staff, and Observer Perspectives
Perry Edelman, Bradley Fulton, Daniel Kuhn, Chih-Hung Chang |
| | PB-027 Galantamine in the Management of Dementia with Lewy Bodies: A 24-week, Open-Label Study
Keith Edwards, Linda Hershey, Stewart Johnson |
| | PB-028 Switching from Donepezil or Rivastigmine to Galantamine in Clinical Practice
Keith Edwards, Judy O'Connor |
| | PB-029 Rivastigmine Can Stabilize Cognitive and Behavioral Decline in Patients with Probable Alzheimer's Disease who Worsen on Donepezil Treatment
Keith R. Edwards, Judy O'Connor, Judy Button, William A. Goodman, Judith Norton |
| | PB-030 Serum Aluminum Levels in Patients with Alzheimer's Disease, Other Dementias and Normal Aging
George El-Nimr, Emad Salib |
| | PB-031 Maintenance of Cognition for 24 Months with Galantamine in Dementia with Cerebrovascular Disease
Timo Erkinjuntti, Sean Lilienfeld, ChandrasekharRao Venkata Damaraju |
| | PB-032 Donepezil Provides Significant Benefits on Cognition, Global Function, and Activities of Daily Living in Patients with Vascular Dementia
K Farcnik, RD Pratt, CA Perdomo |
| | PB-033 Satisfaction and Compliance with Galantamine Therapy Among Patients, Caregivers, and Physicians
Morgan P. Feely, Joan Amatniek, Kay Sadik |
| | PB-034 Correlating Functional and Cognitive Decline in Patients with Mild-to-Moderate Alzheimer’s Disease
Howard Feldman, Shane Kavanagh, Bart Van Baelen |
| | PB-035 The Benefits of Donepezil in Patients with Moderate-to-Severe Alzheimer’s Disease are Independent of Baseline Dementia Severity
H Feldman, S Gauthier, J Hecker, B Vellas, Y Xu, J Ieni, E Schwam |
| | PB-036 Long-Term Treatment with the NMDA Antagonist, Memantine: Results of a 24-Week, Open-Label Extension Study in Moderate to Severe Alzheimer’s Disease
Steven H. Ferris, Frederick A. Schmitt, Rachelle Doody, Hans-Jörg Möbius, Albrecht Stöffler, Barry Reisberg |
| | PB-037 Galantamine for the Treatment of Mild Cognitive Impairment: 2 Double-Blind, Placebo-Controlled Studies
Michael Gold, Daniel Wang, Luc Truyen |
| | PB-038 Efficacy and Tolerability of Memantine in Nursing Home Patients with Moderate-to-Severe Dementia of the Alzheimer’s Type
Bengt Winblad, Stephen Graham, Grace Lee, Hans-Jörg Möbius, Scott McDonald |
| | PB-039 Safety and Tolerability of Memantine in the Treatment of Patients with Vascular Dementia
Stephen Graham, Grace Lee, Margaret Goetz, Yvonne Wirth |
| | PB-040 Mathematical Modeling of Facial Emotion Perceptions on Elderly
Philippe Granato, Raymond Bruyer, Nawal Waucquier, Jean-Pierre Van Gansberghe, Stephane Duhem, Christian Libersa |
| | PB-041 Risk of Cerebrovascular Adverse Events, Including Mortality, with Risperidone in Elderly Patients
Andrew Greenspan, Marielle Eerdekens, Ramy Mahmoud |
| | PB-042 Rivastigmine May Benefit Patients with Alzheimer’s Disease (AD) Who Have Failed to Benefit from Previous Donepezil Treatment
George Grossberg |
| | PB-043 Risk Factors for Incident Alzheimer's Disease in the Indianapolis-Ibadan Comparative Epidemiological Study
Oye Gureje, Kathleen S Hall, Kathlene Lane |
| | PB-044 Individual Differences on Depression in a Brazilian Geriatric Sample
Amer Cavalheiro Hamdan, Orlando Franscisco Amodeo Bueno |
| | PB-045 26-Week Clinical Trial of Galantamine in Patients with Alzheimer's Disease: Comparison Between the Patients Previously Exposed to Other Acetylcholinesterase Inhibitors and Those Never Exposed
Myeong-Il Han, Hyeong-Mo Gu, Hyoung-Suk Lee, Ki-Rip Jung, Doh Kwan Kim |
| | PB-046 Severity of Alzheimer Type Dementia and the Significance of a Dementia Test Battery
Toshihiko Hashidume, Fumitoshi Kodaka, Yoko Takanashi, Hirohide Kada, Haruko Furukawa, Hiroo Kasahara, Sadanobu Ushijima |
| | PB-047 Differential Effects of Olanzapine versus Risperidone on Extrapyramidal Disorders in Adult and Elderly Patients
Donald Hay, Christopher Kaiser, Vicki Poole Hoffmann, Hillary McGuire, Alan P Siegel |
| | PB-048 EXPRESS: A Prospective, Placebo-Controlled Study of Rivastigmine in Parkinson’s Disease Dementia
Martina Herrmann |
| | PB-049 Galantamine Added to the Treatment Regimen for Adult Autism
Marc Hertzman |
| | PB-050 A Placebo-Controlled 10-Week Prospective Comparison of the Occurrence of Falls in Dementia: Olanzapine versus Risperidone
Vicki Poole Hoffmann, John S. Kennedy, Carrie A. Young, Peter D. Feldman, Walter Deberdt |
| | PB-051 Use of Donezepil in Traumatic Brain Injury with Chronic Subdural Hematoma: A Case Presentation
William Hwang, Brigid Byrne |
| | PB-052 A Strategy to Optimize Pharmacotherapy in Nursing Homes by Drug Revisions
Erik G. Jedenius, Stellan Båtsman, Anders Bergström, Bo Henricson, Bengt Winblad, Niels Andreasen |
| | PB-053 Cognition is Physicians’ Main Indicator of Treatment Efficacy in Alzheimer’s Disease Patients
P Johannsen, P Dautzenberg, R Holub, S Jakobsen, C Karageorgiou, I Kloszewska, A Kurz, M Lambert, M Trixler, L Bergendorff, Y Xu, N Kumar, S Richardson |
| | PB-054 Neuropsychological Benefit of Galantamine in Patients with Alzheimer's Disease During 26-Week Clinical Trial
Ki-Rip Jung, Hyeong-Mo Gu, Hyoung-Suk Lee, Myeong-Il Han, Doh Kwan Kim |
| | PB-055 Risk of Falls in Patients with Dementia: Analysis of a Randomized, Placebo-Controlled Risperidone Trial
Ira Katz, Lon Schneider, Chris M. Kosma, Marcia F.T. Rupnow |
| | PB-056 The Effect of Donepezil on Cognitive Functions in Patients with Alzheimer's Disease with Poor Therapeutic Effect after Rivastigmine Treatment
Andrzej Kêpa, Ewa Pilaczyñska, Janusz Rybakowski, Alina Borkowska |
| | PB-057 Galantamine Offers Significant Benefits for Patients with Very Mild Alzheimer’s Disease
Jean-Marc Orgogozo, Gerry Hammond, Susanne Schwalen, Paul Kershaw |
| | PB-058 Predictors of quality of life in stroke patients
Do-Hoon Kim, Yoo-Sun Moon, Byeong-Kil Yeon, Hyon-Chul Kim |
| | PB-059 Factors Associated with Functional Dependence in a Presenile Community Elderly Population in Korea
Hee-Cheol Kim, Jonghan Park, Young-Min Shin |
| | PB-060 Nightmares Induced by Acetylcholinestrase Inhibitor
Jaehyun Kim, Namjin Lee |
| | PB-061 Psychotic Symptoms Recurred by Achetylcholinestrase Inhibitors in Alzheimer's Dementia
Jaehyun Kim, Namjin Lee, Jonghan Park |
| | PB-062 Incidence of Presumptive Tardive Dyskinesia in Elderly Patients Treated with Olanzapine or Conventional Antipsychotics
Bruce J. Kinon, Virginia L. Stauffer, Christopher Kaiser, Donald P. Hay, Sara Kollack-Walker |
| | PB-063 Association Between Depression and Social Support in the Japanese Elderly Population
Yayoi Koizumi, Shuichi Awata, Toru Seki, Naoki Nakaya, Shinichi Kuriyama, Kazuki Fujita, Kaori Ohmori, Atsushi Hozawa, Satoru Ebihara, Hiroyuki Arai, Ryoichi Nagatomi, Hiroo Matsuoka, Ichiro Tsuji |
| | PB-064 Characteristics of Patients Enrolled in a Long-Term Treatment Study of Probable Vascular Dementia and Alzheimer's Disease with Cerebrovascular Disease
Amos Korczyn, Sean Lilienfeld |
| | PB-065 Long-Term Safety, Tolerability, and Efficacy of Galantamine in the Treatment of Probable Vascular Dementia or Alzheimer's Disease with Cerebrovascular Disease: An Interim Analysis
Alexander Kurz, Timo Erkinjuntti, Roger Bullock, Sean Lilienfeld, H. Robert Brashear |
| | PB-066 Galantamine, the Beta-Amyloid Precursor Protein and Amyloid Beta Peptides
Debomoy K Lahiri, G.M. Alley, Sohel Sachak, Martin R. Farlow |
| | PB-067 The Relationship Between Agitation and Decreased Motivation in Nursing Home Residents: The Concept of a "Mixed Behavioral State"
Adrian Leibovici |
| | PB-068 Chronic Exposure to Anticholinergic Medications Adversely Affects the Course of Alzheimer’s Disease
Ching-ju Lu, Larry E. Tune |
| | PB-069 The Clock Drawing Test Can Be a Single Screening Test? Results' Correlation with the Cambridge Cognitive Examination (CAMCOG) for Dementia
José Eduardo Martinelli, Ivan Aprahamian, Renata Vasconcellos Regazzini, Benito Pereira Damasceno |
| | PB-070 Cognitive Impairment and Dectection Rates in Geriatric Primary Care
Zoran Martinovich, Sanford I. Finkel, Robyn Golden, Judy Statsinger |
| | PB-071 Rivastigmine Superior to Aspirin Plus Nimodipine in Subcortical Vascular Dementia
Rita Moretti, Paola Torre, Rodolfo Antonello, Guiseppe Cazzato, Antonio Bava |
| | PB-072 Brazilian Version of the Quality of Life in Alzheimer’s Disease Evaluation Scale (QOL-AD): Results of the Cross-Cultural Adaptation and Internal Validity
Marcia Maria Pires Camargo Novelli, Heloisa Rovere, Ricardo Nitrini, Paulo Caramelli |
| | PB-073 Presentations of Depression in Older Adults
Lisa L. Onega, Barbara J. Stewart, Jonathan Fields |
| | PB-074 Frontal Lobe Dysfunction in the Eldest Patients with Parkinson’s Disease
Grzegorz Opala, Barbara Jasinska-Myga, Agnieszka Gorzkowska, Stanislaw Ochudlo |
| | PB-075 Mini-Memory Test for Easy and Brief Memory Screening
Jonghan Park, Hee-Cheol Kim, Jae-Hyun Kim |
| | PB-076 Pharmacokinetic Study of Memantine and Donepezil in Healthy Young Subjects
Antonia Periclou, Daniel Ventura, Tyler Sherman, Niranjan Rao, Wattanaporn Abramowitz |
| | PB-077 Galantamine is Safe and Effective in Patients with Mild-to-Moderate Alzheimer’s Disease Taking a Wide Range of Concomitant Medications
Tuula Pirttila, Michael Gold, ChandrasekharRao Venkata Damaraju |
| | PB-078 Electro Convulsive Therapy in Older People: A Retrospective Case Note Study
Graham Christopher Pluck, Declan McLoughlin |
| | PB-079 Positive Aspects of Caring for People with Dementia
Nitin Bhalchandra Purandare, Rohana Ramchandran, Anne-Marie Hendry, Alistair Burns |
| | PB-080 Neurobehavioral Outcome of Mild-to-Moderate Traumatic Brain Injury in the Elderly: The Acute Picture
Mark Jeffrey Rapoport, Andrea Lorraine Phillips, Anthony Feinstein |
| | PB-081 Orientation Deficits Precede Rapid Cognitive Decline in Nursing Home Residents with Alzheimer’s Disease
Michael A. Rapp, Richard C. Mohs, Mary Sano, Michael Wysocki, Kelly Ware, Ruby Kesar, Deborah Marin, Hillel Z. Grossman, Vahram Haroutunian |
| | PB-082 Predictors of Longitudinal Change in Cognition in Very Old Nursing Home Residents
Michael A. Rapp, Richard C. Mohs, Mary Sano, Michael Wysocki, Ruby Kesar, Kelly Ware, Deborah Marin, Vahram Haroutunian, Hillel Z. Grossman |
| | PB-083 Long-Term Cognitive Response to Galantamine in Patients with Mild-to-Moderate Alzheimer's Disease: A Continuance Analysis
Murray Raskind, Elaine Peskind, Paul Kershaw, Atul R. Mahableshwarkar |
| | PB-084 The Program of Medical, Psychological, and Social intervention for Family Caregivers of Patients with Dementia
O. Razlog, I. Fojcik, D. Maximenco, E. Maximenco, L. Razlog, I. Razlog |
| | PB-085 Immediate Switch From Donepezil to Rivastigmine is Well Tolerated in Mildly to Moderately Severe Alzheimer’s Disease Patients
Carl Sadowsky, Jennifer Steadman, Leone Atkinson, Barbara Koumaras, James Lee, Dario Mirski |
| | PB-086 Observable Effects of Animal-Assisted Therapy Using Dogs
Ingibjorg Hjaltadottir, Asta B. Petursdottir, Gerdur Saemundsdottir, Gudrun L. Vikingsdottir, Ida Atladottir |
| | PB-087 Variation in Use of the Physical Restraints and Neuroleptics in Different Settings: Why?
Per Olof Sandman, Stig Karlsson |
| | PB-088 A 4-Weekly Dose Escalation Schedule Improves Gastrointestinal Tolerability of Rivastigmine
Jan Schadrack, Fraser Inglis |
| | PB-089 Use of Intravenous Valproate (Depacon) in the Treatment of Delirium: A Case Series
Alan Louis Schneider |
| | PB-090 Estrogen Replacement Therapy and Cognitive Function in Postmenopausal Women
Jeong Seok Seo, Beom Woo Nam |
| | PB-091 Medical Student Participation in a Home Visit Program for Mentally Ill Elderly
Ashok P. Sharma, David M. Roane, Gary J. Kennedy, Lisa J. Taylor, Ellen B. Eisenstadt, Maria F. Gomez |
| | PB-092 Remission Rates in Elderly Depressed Patients Treated with Sertraline
Javaid Sheikh, Tal Burt, Cathryn Clary |
| | PB-093 Galantamine Demonstrates Overall Efficacy Regardless of Baseline Disease Severity in Patients with Vascular Dementia or Alzheimer’s Disease with Cerebrovascular Disease
Gary Small, H. Robert Brashear |
| | PB-094 Depressive Symptoms in Younger and Elderly Post Stroke Patients
Ana Luisa Sosa-Ortiz, Martha Margarita Gonzalez Gonzalez |
| | PB-095 P300 in Newly Diagnosed Non-Dementing Elderly Patients of Parkinson’s Disease: Effect of Levodopa Therapy
Trilochan Srivastava |
| | PB-096 Fukuyama Yuai-Outdoor Activity Care Program (FY-OACP) Improves Quality of Life in the Demented Elderly : Validity and Usefulness of the Recently Developed Japanese Quality of Life Inventory for the Elderly with Dementia (QOL-D)
Shuso Suemaru, Kazuko Harada, Yuki Shimoe, Yukito Maeba, Sachiko Yamasaki, Kozue Kitamura, Izumi Mikami, Eizo Nakada, Koso Suemaru |
| | PB-097 The Effect of ECT on Middle-Aged and Elderly Patients with Intractable Catatonic Schizophrenia
Kazumasa Suzuki, Shuichi Awata, Hiroo Matsuoka |
| | PB-098 Memantine/Donepezil Dual Therapy is Superior to Placebo/Donepezil Therapy for Treatment of Moderate to Severe Alzheimer’s Disease
Pierre N. Tariot, Martin R. Farlow, George Grossberg, Ivan Gergel, Stephen Graham, James Jin |
| | PB-099 A Double-Blind, Randomized Controlled Clinical Trial of TIANZHI Granule in Treatment of Mild-to-Moderate Vascular Dementia in China
Jinzhou Tian, Aihua Zhu, Jing Shi, Jian Zhong, Shulian Peng, Xianfeng Liu, Yongyan Wang |
| | PB-100 Relationship of Drugs, Alcohol and Tobacco Addiction with the Development of Alzheimer’s Disease (AD)
Achyut Trivedi |
| | PB-101 Assessment of the Efficacy of Donepezil Hydrochloride on Cognitive Function in Patients with Dementia of Alzheimer's Type Using WAIS-R
Akinori Ueki, Yoshio Morita |
| | PB-102 Satisfaction with life - one parameter for defining social care of the elderly
Elena S. Vvedenskaya, Irina I. Vvedenskaya, Yury N. Phylippov |
| | PB-103 Maximizing and Maintaining Function for Persons with Alzheimer's Disease Using Non-Pharmacologic Methods
Kim Warchol |
| | PB-104 Galantamine Demonstrates Clinical Effects in a "Real-Life" Clinical Setting
Michael Wasserman |
| | PB-105 Donepezil is a Well-Tolerated Long-Term Treatment for Patients With Mild to Moderate Alzheimer’s Disease: Results From a Patient Cohort Who Completed a One-Year Placebo-Controlled Study and Participated in a Two-Year Follow-Up Study
B Winblad, K Engedal, H Soininen, F Verhey, G Waldemar, A Wimo, A-L Wetterholm, A Haglund, R Zhang, L Burger, R Schindler |
| | PB-106 Long-Term Efficacy and Safety of Galantamine Treatment for 36 Months Compared With Early Discontinuation in Patients With Mild-to-Moderate Alzheimer’s Disease: An International Study
B Winblad, Luc Truyen, Paul Kershaw |
| | PB-107 Long-Term Efficacy of Donepezil in Patients with Mild to Moderate Alzheimer’s Disease: Results From a One-Year Placebo-Controlled Study and Two-Year Follow-up Study
B Winblad, K Engedal, H Soininen, G Waldemar, F Verhey, A Wimo, A-L Wetterholm, A Haglund, R Zhang, L Burger, R Schindler |
| | PB-108 One-Year Outcome of Cholinesterase Inhibitor Therapy in Patients Attending a Memory Clinic
Helen Xuereb, Sarah Baillon, James Lindesay, Steve Perry, Richard Prettyman |
| | PB-109 Validity of Blessed Dementia Rating Scale in Elderly Chinese Population
Yuan-Han Yang, Ruey-Tai Lin, Chih-Ta Tai, Chiou-Lian Lai, Ching-Kuan, Liu |
| | PB-110 Mild Neurocognitive Disorder: Treatment with Galantamine
Julio Zarra, Luisa Schmidt |